Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19

J Formos Med Assoc. 2021 Dec;120(12):2186-2190. doi: 10.1016/j.jfma.2021.04.010. Epub 2021 Apr 21.

Abstract

We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day onset but decreased on 157th day after symptoms.

Keywords: Antiretroviral therapy; Coronavirus; Enzyme-linked immunosorbent assay (ELISA); Plaque reduction assay; Severe acute respiratory syndrome.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19*
  • Enzyme-Linked Immunosorbent Assay
  • HIV Infections* / complications
  • Humans
  • Immunoglobulin G
  • SARS-CoV-2

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin G